Prelude Therapeutics Inc SEC filings PRLD
Prelude Therapeutics Inc has 389 filings in SEC EDGAR's recent list, going back to Jul 11, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 8, 2026 | — |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
| 4 | Insider transaction | May 4, 2026 | May 1, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 9, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 28, 2026 | — |
| 4 | Insider transaction | Apr 28, 2026 | Apr 27, 2026 |
| 3 | Initial insider ownership | Apr 28, 2026 | Apr 21, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 23, 2026 | — |
| 4 | Insider transaction | Apr 23, 2026 | Apr 21, 2026 |
| 4 | Insider transaction | Apr 23, 2026 | Apr 21, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 22, 2026 | — |
| 4 | Insider transaction | Apr 22, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 21, 2026 | Apr 20, 2026 |
| 424B5 | Prospectus supplement | Apr 21, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 20, 2026 | Apr 20, 2026 |
| 3 | Initial insider ownership | Apr 15, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 15, 2026 | Apr 15, 2026 |
| 3 | Initial insider ownership | Mar 19, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Other events
|
Mar 12, 2026 | Mar 12, 2026 |
| 424B5 | Prospectus supplement | Mar 12, 2026 | — |
| S-8 | Employee stock plan registration | Mar 10, 2026 | — |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 10, 2026 | Mar 10, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Feb 5, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 3, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2026 | Jan 9, 2026 |
| EFFECT | Filing | Dec 16, 2025 | — |
| CORRESP | Letter to the SEC | Dec 15, 2025 | — |
| S-3 | Shelf registration | Dec 10, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2025 | Nov 12, 2025 |
| 4 | Insider transaction | Nov 7, 2025 | Nov 5, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 7, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Nov 4, 2025 | Nov 3, 2025 |
| 4 | Insider transaction | Oct 20, 2025 | Oct 17, 2025 |
| 3 | Initial insider ownership | Oct 20, 2025 | Oct 17, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 7, 2025 | Oct 4, 2025 |
| 8-K |
Current report
Other events
|
Sep 19, 2025 | Sep 18, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2025 | Aug 14, 2025 |
| 4 | Insider transaction | Jul 8, 2025 | Jul 4, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 13, 2025 | — |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 3 | Initial insider ownership | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 13, 2025 | Jun 11, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Other events
|
Apr 25, 2025 | Apr 25, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 8-K |
Current report
Listing notice
|
Mar 28, 2025 | Mar 27, 2025 |
| 4 | Insider transaction | Mar 27, 2025 | Mar 25, 2025 |
| 4 | Insider transaction | Mar 27, 2025 | Mar 25, 2025 |
| 4 | Insider transaction | Mar 24, 2025 | Mar 20, 2025 |
| 4 | Insider transaction | Mar 18, 2025 | Mar 14, 2025 |
| 4 | Insider transaction | Mar 14, 2025 | Mar 12, 2025 |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| 10-K | Annual report | Mar 10, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 10, 2025 | Mar 10, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2025 | — |
| 4 | Insider transaction | Feb 5, 2025 | Feb 4, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 4, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 4, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 4, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 4, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Jan 7, 2025 | Jan 4, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Jan 2, 2025 | Dec 30, 2024 |
| 4 | Insider transaction | Dec 26, 2024 | Dec 20, 2024 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| 8-K |
Current report
Other events
|
Dec 11, 2024 | Dec 11, 2024 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Other events
|
Oct 24, 2024 | Oct 24, 2024 |
| 4 | Insider transaction | Oct 7, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Other events
|
Sep 13, 2024 | Sep 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2024 | Sep 9, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2024 | Aug 12, 2024 |
| 4 | Insider transaction | Jul 8, 2024 | Jul 4, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 12, 2024 | Jun 12, 2024 |
| EFFECT | Filing | Jun 10, 2024 | — |
| CORRESP | Letter to the SEC | Jun 6, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2024 | — |
| S-3 | Shelf registration | May 30, 2024 | — |
| 8-K/A |
Amended current report
Officer or director change
|
May 16, 2024 | Apr 8, 2024 |
| 4 | Insider transaction | May 16, 2024 | May 14, 2024 |
| EFFECT | Filing | May 8, 2024 | — |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| CORRESP | Letter to the SEC | May 6, 2024 | — |
| S-3/A | Filing | May 6, 2024 | — |
| CORRESP | Letter to the SEC | May 3, 2024 | — |
| CORRESP | Letter to the SEC | May 1, 2024 | — |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 10, 2024 | Apr 8, 2024 |
| 4 | Insider transaction | Apr 8, 2024 | Apr 4, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| 4 | Insider transaction | Mar 4, 2024 | Mar 1, 2024 |
| UPLOAD | Letter from the SEC | Feb 21, 2024 | — |
| S-3 | Shelf registration | Feb 16, 2024 | — |
| S-8 | Employee stock plan registration | Feb 16, 2024 | — |
| 10-K | Annual report | Feb 15, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 15, 2024 | Feb 15, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 10, 2024 | — |
| 4 | Insider transaction | Jan 8, 2024 | Jan 4, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Dec 13, 2023 | — |
| 4 | Insider transaction | Dec 13, 2023 | Dec 13, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 11, 2023 | Dec 11, 2023 |
| SC 13G | Ownership over 5% (passive) | Nov 13, 2023 | — |
| 10-Q | Quarterly report | Nov 1, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2023 | Nov 1, 2023 |
| 4 | Insider transaction | Oct 6, 2023 | Oct 4, 2023 |
| 10-Q | Quarterly report | Aug 3, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 3, 2023 | Aug 3, 2023 |
| 4 | Insider transaction | Jul 6, 2023 | Jul 4, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 1, 2023 | Jun 1, 2023 |
| 4 | Insider transaction | May 26, 2023 | May 24, 2023 |
| 4 | Insider transaction | May 25, 2023 | May 24, 2023 |
| 4 | Insider transaction | May 25, 2023 | May 23, 2023 |
| 4 | Insider transaction | May 25, 2023 | May 23, 2023 |
| 4 | Insider transaction | May 24, 2023 | May 22, 2023 |
| 4 | Insider transaction | May 24, 2023 | May 22, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | May 24, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 24, 2023 | — |
| 4 | Insider transaction | May 24, 2023 | May 22, 2023 |
| 424B5 | Prospectus supplement | May 19, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
May 19, 2023 | May 18, 2023 |
| FWP | Free writing prospectus | May 18, 2023 | — |
| 424B5 | Prospectus supplement | May 17, 2023 | — |
| 8-K |
Current report
Other events
|
May 17, 2023 | May 17, 2023 |
| 10-Q | Quarterly report | May 8, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 8, 2023 | May 8, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 16, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Apr 6, 2023 | Apr 4, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 15, 2023 | Mar 15, 2023 |
| 424B5 | Prospectus supplement | Mar 15, 2023 | — |
| S-8 | Employee stock plan registration | Mar 15, 2023 | — |
| 10-K | Annual report | Mar 15, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Mar 15, 2023 | Mar 15, 2023 |
| 4 | Insider transaction | Mar 2, 2023 | Mar 1, 2023 |
| 3 | Initial insider ownership | Feb 22, 2023 | Feb 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 14, 2023 | Feb 14, 2023 |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2023 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRLD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1678660
- Former names
- Prelude Therapeutics Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.